HuidaGene Therapeutics Secures FDA Approval for HG202, the First CRISPR/Cas13 RNA-Editing Treatment for Macular Degeneration.

Cytoki Pharma has dosed the first patient in its Phase 2 trial for CK-0045, targeting obesity and Type 2 diabetes.

Ibrutinib is a medication used primarily in the treatment of certain types of cancer, particularly B-cell malignancies.

Viking Therapeutics has announced that new clinical findings from its VK2735 obesity initiative were featured in two poster sessions at ObesityWeek® 2024.

Recently,the Center for Drug Evaluation of the NMPA announced the acceptance of the investigational new drug (IND) application for Novartis's PIT565 injection.

Ionis has revealed that the FDA has accepted the New Drug Application for donidalorsen, intended for the preventive treatment of HAE.

Tiziana Life Sciences announced that its intranasally administered anti-CD3 monoclonal antibody, foralumab.

CinFina Pharma showcases encouraging Phase 1 study findings during a poster session for CIN-109 and a late-breaking poster for CIN-110.

Recently, Vivoryon Therapeutics presented new analysis data for varoglutamstat at the 2024 American Society of Nephrology (ASN) meeting.

Xencor has administered the initial dose to a participant in the Phase 1/2 trial of XmAb®942, aimed at treating inflammatory bowel disease.

Givosiran Sodium, a groundbreaking therapeutic agent, is a small interfering RNA (siRNA) developed by Alnylam Pharmaceuticals.

HiFiBiO Therapeutics has gained FDA approval for its IND application concerning HFB200604, a leading BTLA agonist antibody.